Abpro Holdings, Inc. (ABP)

Market Cap	13.22M
Revenue (ttm)	183,000
Net Income (ttm)	-17.41M
Shares Out	51.24M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	277,597
Open	0.2500
Previous Close	0.2460
Day's Range	0.2361 - 0.2500
52-Week Range	0.2300 - 13.0000
Beta	-0.08
Analysts	Strong Buy
Price Target	4.00 (+1,520.09%)
Earnings Date	May 18, 2025

About ABP

Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues. Its platform DiversImmune addresses the antibody therapeutics. The company’s product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer. It also offers ABP-105 for the treatment of gastric cancer and ABP 201 for vascular diseases of the eye and diabetic macular edema. Abpro Holdings, Inc. was incorporated in 2004 and is based in Woburn, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: ABP
• Website: https://abpro.com

Financial Performance

In 2023, Abpro Holdings's revenue was $122,000, a decrease of -93.99% compared to the previous year's $2.03 million. Losses were -$11.71 million, -32.00% less than in 2022.

Analyst Forecast

According to one analyst, the rating for ABP stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target

$4.0

(1,520.09% upside)

Analyst Consensus: Strong Buy